After rumors ignited speculation last month, a KKR buyout of India's Gland Pharma may be on the way, according to Reuters' sources. The private equity firm will reportedly pay about $150 million for nearly 30% of the drugmaker, which makes heparin and some other products for the cardiovascular and orthopedic segments. For KKR, the deal would follow up on a string of recent healthcare investments. Last month, it agreed to buy a $1.67 billion stake in Panasonic's healthcare arm and sealed a deal to buy and merge PRA and ReSearch Pharmaceutical Services, creating the world's fourth-largest CRO in the process. Story | More